GlassScriptPhysician profile
Rhonda Green
NPI 1649370032
$2,296.64
in general payments reported to CMS, 2019-2025
26 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $144 · 2021: $213 · 2022: $347 · 2023: $348 · 2024: $171 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.74 | 2019-2025 | |
| Lilly USA, LLC | $255.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $254.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $252.28 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $204.23 | 2021-2025 | |
| Amgen INC. | $125.40 | 2019-2023 | Prolia, Evenity |
| Mylan Specialty L.P. | $112.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $109.07 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $82.73 | 2019-2022 | |
| Astellas Pharma US INC | $81.01 | 2019 | |
| Merck Sharp & Dohme LLC | $73.15 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.41 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.70 | 2019-2022 | |
| Amarin Pharma, INC. | $48.60 | 2021-2022 | |
| Abbott Laboratories | $39.90 | 2021-2023 | Freestyle Libre 2 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.65 | 2022-2025 | |
| Eisai INC. | $31.74 | 2019 | |
| Exact Sciences Corporation | $27.83 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $15.39 | 2021 | |
| Pfizer INC. | $15.36 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.57 | 2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.66 | 2025 | Caplyta |
| Almatica Pharma LLC | $13.33 | 2021 | |
| Allergan, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.